287 related articles for article (PubMed ID: 9949863)
21. [The role of serotonin and serotonin receptors in the pathogenesis of migraine and in the mechanisms of action of anti-migraine drugs].
Amelin AV; Skoromets AA; Ignatov IuD
Zh Nevrol Psikhiatr Im S S Korsakova; 2000; 100(7):55-8. PubMed ID: 10957805
[No Abstract] [Full Text] [Related]
22. Effect of a serotonin agonist (sumatriptan) on the peptidergic innervation of the rat cerebral dura mater and on the expression of c-fos in the caudal trigeminal nucleus in an experimental migraine model.
Knyihár-Csillik E; Tajti J; Samsam M; Sáry G; Slezák S; Vécsei L
J Neurosci Res; 1997 Jun; 48(5):449-64. PubMed ID: 9185668
[TBL] [Abstract][Full Text] [Related]
23. Current and emerging second-generation triptans in acute migraine therapy: a comparative review.
Deleu D; Hanssens Y
J Clin Pharmacol; 2000 Jul; 40(7):687-700. PubMed ID: 10883409
[TBL] [Abstract][Full Text] [Related]
24. Serotonin receptor ligands: treatments of acute migraine and cluster headache.
Goadsby PJ
Handb Exp Pharmacol; 2007; (177):129-43. PubMed ID: 17087122
[TBL] [Abstract][Full Text] [Related]
25. Dural vasodilation causes a sensitization of rat caudal trigeminal neurones in vivo that is blocked by a 5-HT1B/1D agonist.
Cumberbatch MJ; Williamson DJ; Mason GS; Hill RG; Hargreaves RJ
Br J Pharmacol; 1999 Mar; 126(6):1478-86. PubMed ID: 10217543
[TBL] [Abstract][Full Text] [Related]
26. [Role of serotonin and other neuroactive molecules in the physiopathogenesis of migraine. Current hypotheses].
Hamon M; Bourgoin S
Pathol Biol (Paris); 2000 Sep; 48(7):619-29. PubMed ID: 11072640
[TBL] [Abstract][Full Text] [Related]
27. 5-HT1F receptor agonists inhibit neurogenic dural inflammation in guinea pigs.
Johnson KW; Schaus JM; Durkin MM; Audia JE; Kaldor SW; Flaugh ME; Adham N; Zgombick JM; Cohen ML; Branchek TA; Phebus LA
Neuroreport; 1997 Jul; 8(9-10):2237-40. PubMed ID: 9243618
[TBL] [Abstract][Full Text] [Related]
28. Preclinical studies characterizing the anti-migraine and cardiovascular effects of the selective 5-HT1D receptor agonist PNU-142633.
McCall RB; Huff R; Chio CL; TenBrink R; Bergh CL; Ennis MD; Ghazal NB; Hoffman RL; Meisheri K; Higdon NR; Hall E
Cephalalgia; 2002 Dec; 22(10):799-806. PubMed ID: 12485205
[TBL] [Abstract][Full Text] [Related]
29. Differential effects of 5-HT1B/1D receptor agonists on neurogenic dural plasma extravasation and vasodilation in anaesthetized rats.
Shepherd SL; Williamson DJ; Beer MS; Hill RG; Hargreaves RJ
Neuropharmacology; 1997; 36(4-5):525-33. PubMed ID: 9225277
[TBL] [Abstract][Full Text] [Related]
30. Migraine: current concepts and emerging therapies.
Arulmozhi DK; Veeranjaneyulu A; Bodhankar SL
Vascul Pharmacol; 2005 Sep; 43(3):176-87. PubMed ID: 16099727
[TBL] [Abstract][Full Text] [Related]
31. Evidence for 5-HT1B/1D receptors mediating the antimigraine effect of sumatriptan and dihydroergotamine.
Buzzi MG; Moskowitz MA
Cephalalgia; 1991 Sep; 11(4):165-8. PubMed ID: 1660351
[TBL] [Abstract][Full Text] [Related]
32. An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy.
Villalón CM; Centurión D; Valdivia LF; De Vries P; Saxena PR
Proc West Pharmacol Soc; 2002; 45():199-210. PubMed ID: 12434581
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of 5HT in migraine.
Buzzi MG
Cephalalgia; 1999 Sep; 19(7):625-6. PubMed ID: 10524654
[No Abstract] [Full Text] [Related]
34. Receptor specificity and trigemino-vascular inhibitory actions of a novel 5-HT1B/1D receptor partial agonist, 311C90 (zolmitriptan).
Martin GR; Robertson AD; MacLennan SJ; Prentice DJ; Barrett VJ; Buckingham J; Honey AC; Giles H; Moncada S
Br J Pharmacol; 1997 May; 121(2):157-64. PubMed ID: 9154322
[TBL] [Abstract][Full Text] [Related]
35. 5-HT(1)-like receptor agonists and the pathophysiology of migraine.
Saxena PR; Ferrari MD
Trends Pharmacol Sci; 1989 May; 10(5):200-4. PubMed ID: 12722735
[TBL] [Abstract][Full Text] [Related]
36. Mechanisms of action of the 5-HT1B/1D receptor agonists.
Tepper SJ; Rapoport AM; Sheftell FD
Arch Neurol; 2002 Jul; 59(7):1084-8. PubMed ID: 12117355
[TBL] [Abstract][Full Text] [Related]
37. Comparison of more and less lipophilic serotonin (5HT1B/1D) agonists in a model of trigeminovascular nociception in cat.
Hoskin KL; Goadsby PJ
Exp Neurol; 1998 Mar; 150(1):45-51. PubMed ID: 9514827
[TBL] [Abstract][Full Text] [Related]
38. Review of zolmitriptan and its clinical applications in migraine.
Dowson AJ; Charlesworth B
Expert Opin Pharmacother; 2002 Jul; 3(7):993-1005. PubMed ID: 12083998
[TBL] [Abstract][Full Text] [Related]
39. The Role of 5-Hydroxytryptamine in the Pathophysiology of Migraine and its Relevance to the Design of Novel Treatments.
Villalón CM; VanDenBrink AM
Mini Rev Med Chem; 2017; 17(11):928-938. PubMed ID: 27465216
[TBL] [Abstract][Full Text] [Related]
40. 5-HT(1F) Receptor agonists: a new treatment option for migraine attacks?
Neeb L; Meents J; Reuter U
Neurotherapeutics; 2010 Apr; 7(2):176-82. PubMed ID: 20430316
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
